glp-1 statistics Use Has More Than Quadrupled Since 2021 as Obesity Rates Continue to Show Signs of Decline Glucagon Like Peptide-1 (GLP-1) Agonists
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 19.Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S
This is relevant because GLP-1 users often lose both fat and lean muscle mass during treatment, and muscle-related side effects are a common concern
Some begin noticing subtle changes in appetite and cravings, but these are not universal at this stage
Divergent Tissue-Specific and Developmental Expression of Receptors for Glucagon and Glucagon-like Peptide-1 in the Mouse
Lilly expects to share the study results at a diabetes conference and in a peer-reviewed medical journal later this year
Alawami F, Al Hajjaj A
